Fda Approves Bristol Myers Squibb’s New Oral Medication For Schizophrenia Treatment - Luminary Times
Chris Boerner, board chair and CEO of Bristol Myers Squibb, emphasised the importance of this development, describing it as a transformative moment in the
Similar Snaps
luminarytimes
46 Snaps
-
55
-
0
- Details
- Date Found Oct 02, 2024